Myth 1: Antidepressants Are More Effective than Placebos
Myth 2: If the First Antidepressant Fails, Another Antidepressant Will Likely Succeed
Myth 3: Electroconvulsive Treatment (ECT) is an Effective Last Resort
Myth 4: Cognitive Behavior Therapy (CBT) is the Best Psychotherapy for Depression
Myth 5: No Treatment for Depression Works
Although the Oregon State Hospital was not specifically named in Ken Kesey’s novel, on which the 1975 Academy-award winning movie was based, it could have been. For its legacy of real abuses spans over a century.
Although the chilling film starring Jack Nicholson is now decades old, it wasn’t until state lawmakers toured the facility in 2004 that they discovered the cremated remains of 3,600 patients who had been locked away and forgotten inside. “You can see the place where they showered. You can see their scratchings on the wall,” said Oregon Senate President Peter Courtney. “They lived there. And then often people forgot them. They just took them there and it was over.”
A lawsuit that alleges Wyeth executives told a series of lies about the antidepressant Pristiq — suggesting that it was a good treatment for post-menopause hot-flashes when they were sitting on study data showing a risk of heart and liver problems — gives new guidance to management on what counts as a false or misleading disclosure to investors.
In the case, the judge ruled that front-loading your investor presentations with a bunch of boilerplate language about “safe-harbor” predictions and “forward-looking statements” that ought to be treated with caution does not allow you to stay silent about negative data that you know will affect the fortunes of your company. (The order was reaffirmed just before Thanksgiving.)
Two prominent authors of a 1999 book teaching family doctors how to treat psychiatric disorders provided acknowledgment in the preface for an “unrestricted educational grant” from a major pharmaceutical company. But the drug maker, then known as SmithKline Beecham, actually had much more involvement than the book described, newly disclosed documents show. The grant paid for a writing company to develop the outline and text for the two named authors, the documents show, and then the writing company said it planned to show three drafts directly to the pharmaceutical company for comments and “sign-off” and page proofs for “final approval.” The 269-page book, “Recognition and Treatment of Psychiatric Disorders: A Psychopharmacology Handbook for Primary Care,” is so far the first book among publications, namely medical journal articles, that have been criticized in recent years for hidden drug industry influence, colloquially known as ghostwriting.
A psychiatrist on the payroll of GlaxoSmithKline has been sentenced to 13 months in prison after pleading guilty to committing research fraud in trials of the company’s antidepressant Paxil on children. GlaxoSmithKline, manufacturer of Paxil, paid Palazzo $5,000 for every child she enrolled in the study. The case’s significance goes beyond simple research fraud, as Glaxo is now defending itself against charges that for 15 years it deliberately concealed evidence that Paxil increases the risk of suicide in children. Maria Carmen Palazzo is already serving a sentence of 87 months for defrauding Medicare and Medicaid.
SHARE YOUR STORY/COMMENT: